The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).

Karen A.  Autio

Research Funding - Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Tizona Therapeutics, Inc. (Inst)

Celestia S.  Higano

Employment - CTI BioPharma Corp (I)

Stock and Other Ownership Interests  - CTI BioPharma Corp (I)

Honoraria - Astellas Pharma

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Ferring; Genentech; Hinova Pharmaceuticals; Janssen; Menarini; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer

Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Emergent BioSolutions (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Carrick Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer

Luke T.  Nordquist

No Relationships to Disclose

Leonard Joseph  Appleman

Consulting or Advisory Role - AADi

Research Funding - Acerta Pharma (Inst); Agensys (Inst); Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology (Inst); Tokai Pharmaceuticals (Inst)

Other Relationship - Pfizer

Tian  Zhang

Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)

Stock and Other Ownership Interests  - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)

Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences; Pacific Genuity

Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen

Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis

Research Funding - Acerta Pharma (Inst); Astellas Pharma; Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)

Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)

Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health

Xinhua  Zhu

Consulting or Advisory Role - Immunomedics

Hani M.  Babiker

Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences

Speakers' Bureau - Guardant Health

Nicholas J.  Vogelzang

Employment - US Oncology

Stock and Other Ownership Interests  - Caris Life Sciences

Honoraria - Merck; Novartis; Pfizer; UpToDate

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals

Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas

Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)

Expert Testimony - Novartis

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology

Sandip  Prasad

Consulting or Advisory Role - UroGen pharma

Speakers' Bureau - UroGen pharma

Research Funding - Genomic Health; Merck; Pfizer

Michael Thomas  Schweizer

Consulting or Advisory Role - Resverlogix

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)

Stephane  Billotte

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Joseph  Binder

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Nora  Cavazos

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Ruifeng  Li

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Kam  Chan

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Helen  Cho

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Michael  Dermyer

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Research Funding - Pfizer

Patents, Royalties, Other Intellectual Property - US9066898B2 Prostate-associated antigens and vaccine-based immunotherapy regimens

Robert  Hollingsworth

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Kenneth Alan  Kern

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Daniel P.  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Expert Testimony - Celgene; sanofi